Tackling the Problem Head On: Key Considerations for CMV in the Post-Transplant Setting: A Care Team Forum®

Program Overview

Cytomegalovirus (CMV) is a formidable pathogen after solid organ or hematopoietic cell transplant. During this engaging activity, Drs. Humar and Papanicolaou and an experienced patient discuss best practices for CMV prevention and treatment after transplantation. Learn how to incorporate newer therapeutic options for CMV to improve outcomes in your transplant patients.

1.25 CE Credit(s)

Expires: November 7, 2024

Target Audience

Critical care, hematology-oncology, hospitalist, infectious disease, nephrology, pharmacy, primary care, and surgery

Educational Objectives

Upon completion of this activity, participants should be better able to:

Identify patients who are at risk for cytomegalovirus (CMV) infection in the post-transplant setting
Describe the burden associated with CMV infection and its impact on post-transplant outcomes
Utilize prophylactic and preemptive antiviral therapies for the management of CMV in transplant recipients
Integrate new antiviral therapies into management regimens for transplant recipients, including those who develop treatment-refractory or drug-resistant CMV

Activity Faculty

Atul Humar, MD, FRCPC, FAST

Professor, Department of Medicine
University of Toronto
R. Fraser Elliott Chair, Transplantation
University Health Network
Director, University of Toronto Transplant Institute
Toronto, ON, Canada

Genovefa Papanicolaou, MD

Infectious Disease Service
Memorial Sloan Kettering Cancer Center
Professor, Medicine
Weill Cornell Medical College, Cornell University
New York, NY, United States

Supporter Statement

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Provider Statement

This activity is provided by RMEI Medical Education, LLC.

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Atul Humar, MD, FRCPC, FAST, has relevant financial relationships with Roche, Takeda (Consultant).

Genovefa Papanicolaou, MD, has relevant financial relationships with Cidara, CSL Behring, Merck, Symbio, Takeda (Advisor); Merck (Grant/Research Support); AlloVir, Octapharma (Independent Contractor, including contracted research); Merck (Speaker/Speaker’s Bureau).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers

RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number – JA4008290-0000-23-011-H01-P)
Type of Activity: Knowledge.

Method of Participation and Request for Credit

To receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at [email protected].

Users must:

Read the learning objectives and faculty disclosures
Participate in the activity
Complete the activity evaluation

There is no fee to participate.

For Pharmacists: You must provide your NABP eProfile ID and Date of Birth (MMDD format) in order to receive credit for the activity.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!*

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.  

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 